Wuhan Keqian Biology Co Ltd (688526) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wuhan Keqian Biology Co Ltd (688526) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥174.36 Million ≈ $25.51 Million USD) by net assets (CN¥4.17 Billion ≈ $610.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wuhan Keqian Biology Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Wuhan Keqian Biology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Wuhan Keqian Biology Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Wuhan Keqian Biology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Keqian Biology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Sinarmas Tbk
JK:BSIM
|
0.273x |
|
UroGen Pharma Ltd
NASDAQ:URGN
|
0.363x |
|
Tortoise Energy Infrastructure Closed Fund
NYSE:TYG
|
0.017x |
|
Xiangxue Pharmaceutical
SHE:300147
|
0.069x |
|
New Wave Group AB (publ)
ST:NEWA-B
|
0.078x |
|
Hangzhou Advance Gearbox Group Co Ltd
SHG:601177
|
0.028x |
|
Brother Enterprises Holding Co Ltd
SHE:002562
|
0.014x |
|
PM Capital Global Opportunities Fund Ltd
AU:PGF
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Wuhan Keqian Biology Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Wuhan Keqian Biology Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Wuhan Keqian Biology Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.94 Billion ≈ $576.99 Million |
CN¥392.68 Million ≈ $57.46 Million |
0.100x | -28.97% |
| 2023-12-31 | CN¥3.84 Billion ≈ $561.57 Million |
CN¥538.03 Million ≈ $78.73 Million |
0.140x | +15.78% |
| 2022-12-31 | CN¥3.50 Billion ≈ $512.02 Million |
CN¥423.71 Million ≈ $62.00 Million |
0.121x | -28.11% |
| 2021-12-31 | CN¥3.15 Billion ≈ $461.52 Million |
CN¥531.27 Million ≈ $77.74 Million |
0.168x | +14.02% |
| 2020-12-31 | CN¥2.71 Billion ≈ $396.34 Million |
CN¥400.14 Million ≈ $58.55 Million |
0.148x | +6.73% |
| 2019-12-31 | CN¥1.12 Billion ≈ $163.74 Million |
CN¥154.89 Million ≈ $22.67 Million |
0.138x | -65.52% |
| 2018-12-31 | CN¥876.34 Million ≈ $128.24 Million |
CN¥351.83 Million ≈ $51.48 Million |
0.401x | -19.92% |
| 2017-12-31 | CN¥673.41 Million ≈ $98.54 Million |
CN¥337.61 Million ≈ $49.40 Million |
0.501x | -6.16% |
| 2016-12-31 | CN¥413.10 Million ≈ $60.45 Million |
CN¥220.69 Million ≈ $32.29 Million |
0.534x | -- |
About Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.